Literature DB >> 11533004

Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.

O Ciofu1, V Fussing, N Bagge, C Koch, N Høiby.   

Abstract

The purpose of this study was to characterize 42 paired mucoid and non-mucoid Danish cystic fibrosis (CF) Pseudomonas aeruginosa isolates collected in 1997, by RiboPrinting, antibiotic susceptibility and beta-lactamase activity. Eight P. aeruginosa isolates collected before 1991 were included for comparison. Eighteen of the 42 paired mucoid and non-mucoid isolates showed the same ribotype; the remaining 24 belonged to different ribogroups. Mucoid isolates showed higher susceptibility to antibiotics and lower beta-lactamase activity compared with non-mucoid isolates. Significant differences (P < or = 0.01) between mucoid and non-mucoid isolates were found for the meropenem and colistin MICs for the isolates with the same ribotype, and for the MICs of ceftazidime, piperacillin, aztreonam, meropenem, tobramycin, ciprofloxacin and in the basal levels of beta-lactamase for the paired isolates belonging to different ribogroups. A dominant ribotype 73-S2 with hyperinducible beta-lactamase production and significantly higher MICs of piperacillin, meropenem and tobramycin compared with the other major ribotypes (73-S1, 207-S3 and 227-S8) was present among the 84 CF isolates. The isolates collected before 1991 had an antibiotic susceptibility pattern similar to the 1997 isolates. Despite prolonged and intensive antibiotic treatment, susceptible mucoid isolates were isolated from the CF sputum, possibly because these bacteria are protected from the selective pressure of antibiotics by the resistant non-mucoid isolates co-existing in the biofilm in the lungs of CF patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533004     DOI: 10.1093/jac/48.3.391

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

Review 1.  Mechanisms of antibiotic resistance in Pseudomonas aeruginosa.

Authors:  P A Lambert
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Characterization of temporal protein production in Pseudomonas aeruginosa biofilms.

Authors:  Christopher J Southey-Pillig; David G Davies; Karin Sauer
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

3.  Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Baoleri Lee; Janus A J Haagensen; Oana Ciofu; Jens Bo Andersen; Niels Høiby; Søren Molin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 4.  Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.

Authors:  R Trastoy; T Manso; L Fernández-García; L Blasco; A Ambroa; M L Pérez Del Molino; G Bou; R García-Contreras; T K Wood; M Tomás
Journal:  Clin Microbiol Rev       Date:  2018-08-01       Impact factor: 26.132

Review 5.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

6.  Evolutionary remodeling of global regulatory networks during long-term bacterial adaptation to human hosts.

Authors:  Søren Damkiær; Lei Yang; Søren Molin; Lars Jelsbak
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

7.  In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections.

Authors:  Lei Yang; Janus A J Haagensen; Lars Jelsbak; Helle Krogh Johansen; Claus Sternberg; Niels Høiby; Søren Molin
Journal:  J Bacteriol       Date:  2007-12-21       Impact factor: 3.490

8.  Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin.

Authors:  Marwa N Ahmed; Andreas Porse; Morten Otto Alexander Sommer; Niels Høiby; Oana Ciofu
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

9.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

10.  Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis.

Authors:  Claus Moser; Maria Van Gennip; Thomas Bjarnsholt; Peter Østrup Jensen; Baoleri Lee; Hans Petter Hougen; Henrik Calum; Oana Ciofu; Michael Givskov; Søren Molin; Niels Høiby
Journal:  APMIS       Date:  2009-02       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.